Contrasting Enovis (NYSE:ENOV) & Schrodinger (NASDAQ:SDGR)

Schrodinger (NASDAQ:SDGR) and Enovis (NYSE:ENOV) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Profitability

This table compares Schrodinger and Enovis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Schrodinger	-40.37%	-29.47%	-14.69%
Enovis	-52.69%	8.74%	4.19%

Volatility & Risk

Schrodinger has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, Enovis has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500.

Institutional and Insider Ownership

79.1% of Schrodinger shares are held by institutional investors. Comparatively, 98.5% of Enovis shares are held by institutional investors. 21.0% of Schrodinger shares are held by insiders. Comparatively, 2.7% of Enovis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Schrodinger and Enovis”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrodinger	$255.87 million	3.33	-$103.26 million	($1.42)	-8.13
Enovis	$2.25 billion	0.59	-$1.18 billion	($20.71)	-1.13

Schrodinger has higher earnings, but lower revenue than Enovis. Schrodinger is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Schrodinger and Enovis, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrodinger	1	4	4	0	2.33
Enovis	1	0	6	2	3.00

Schrodinger currently has a consensus price target of $21.13, indicating a potential upside of 82.90%. Enovis has a consensus price target of $47.43, indicating a potential upside of 103.20%. Given Enovis’ stronger consensus rating and higher possible upside, analysts clearly believe Enovis is more favorable than Schrodinger.

Summary

Enovis beats Schrodinger on 9 of the 15 factors compared between the two stocks.

About Schrodinger

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.